Condition
    Limited
    Effectiveness 3/5

    Rhodiola Rosea for Chronic Fatigue Syndrome (ME/CFS)

    Rhodiola has the most encouraging adaptogen evidence for stress-driven fatigue, but ME/CFS is a distinct illness with post-exertional malaise at its core, and rhodiola does not address that. Some patients report improved daytime function; none should expect it to change the underlying condition.

    Overview

    Rhodiola has the most encouraging adaptogen evidence for stress-driven fatigue, but ME/CFS is a distinct illness with post-exertional malaise at its core, and rhodiola does not address that. Some patients report improved daytime function; none should expect it to change the underlying condition.

    Verdict

    Mixed evidence

    Reasonable to trial for daytime energy alongside pacing, but it is not a treatment for ME/CFS and must not be used to justify pushing past your energy envelope.

    How It Works

    Rhodiola modulates the HPA axis, blunting exaggerated cortisol responses, and influences serotonin, dopamine and noradrenaline signalling. Salidroside shows antioxidant and mitochondrial-supportive activity in preclinical work, which is the theoretical basis for use in fatigue states with suspected bioenergetic impairment. None of these mechanisms address post-exertional malaise.

    Dosing & Protocol

    Typical dose

    Recommended dose
    200-400 mg standardised extract, morning
    Expected timeframe
    1-4 weeks

    Protocol

    form
    Extract standardised to 3% rosavins and 1% salidroside
    duration
    4-6 weeks against a stable pacing baseline
    co factor
    Do not expand activity if energy improves — the envelope has not changed
    titration
    Increase to 400 mg after two weeks if tolerated
    starting dose
    100-200 mg in the morning on an empty stomach

    Evidence

    What the studies say

    There are no adequately powered randomised trials of rhodiola in diagnosed ME/CFS. The supporting evidence is extrapolated from studies in stress-related fatigue and burnout, where an open trial in 118 people with burnout showed improvement in fatigue and quality of life within a week, and randomised work in physicians on night duty found reduced mental fatigue. Extrapolating from stress-related fatigue to ME/CFS is a substantial leap: the two conditions differ mechanistically, and interventions that help the former have often failed in the latter. Patient-reported outcomes are mixed.

    The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials

    Score: 8/10
    2011
    systematic_review

    Hung SK, Perry R, Ernst E

    R. rosea may have beneficial effects on physical performance, mental performance and certain mental health conditions.

    View source

    Rhodiola rosea in subjects with prolonged or chronic fatigue symptoms: results of an open-label clinical trial

    Score: 5/10
    2017
    observational
    n=100

    Lekomtseva Y, Zhukova I, Wacker A

    The fatigue symptoms continued to decline further, with statistically significant improvement at week 8.

    View source

    A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue

    Score: 7/10
    2009
    rct
    n=60

    Olsson EM, von Scheele B, Panossian AG

    Significant post-treatment improvements were observed for both groups (placebo effect) in Pines burnout scale, mental health (SF-36), and MADRS, with the SHR-5 group showing greater improvement in burnout and attention.

    View source

    Rhodiola rosea for physical and mental fatigue: a systematic review

    Score: 9/10
    2012
    systematic_review

    Ishaque S, Shamseer L, Bukutu C +1 more

    Two of six trials examining physical fatigue in healthy populations report R. rosea to be effective as did three of five RCTs evaluating R. rosea for mental fatigue.

    View source

    Safety

    Caveats

    Rhodiola is mildly activating and can worsen sleep if taken after midday — a serious problem in a condition where unrefreshing sleep is already a core feature. Avoid alongside SSRIs or MAOIs without medical review, and in bipolar disorder.

    Less likely to help if

    People with severe or bedbound ME/CFS rarely report meaningful benefit. Those whose predominant symptom is post-exertional malaise rather than daytime lethargy are unlikely to notice anything.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.